• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

金纳米粒子-生物缀合氨基胍抑制糖基化反应:糖尿病动物模型研究。

Gold Nanoparticle-Bioconjugated Aminoguanidine Inhibits Glycation Reaction: An Study in a Diabetic Animal Model.

机构信息

Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, Saudi Arabia.

Department of Biosciences, Integral University, Lucknow, India.

出版信息

Biomed Res Int. 2021 May 12;2021:5591851. doi: 10.1155/2021/5591851. eCollection 2021.

DOI:10.1155/2021/5591851
PMID:34055984
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8137289/
Abstract

Proteins undergo glycation resulting in the generation of advanced glycation end products (AGEs) that play a central role in the onset and advancement of diabetes-associated secondary complications. Aminoguanidine (AG) acts as an antiglycating agent by inhibiting AGE generation by blocking reactive carbonyl species (RCS) like, methylglyoxal (MGO). Previous studies on antiglycating behavior of AG gave promising results in the treatment of diabetes-associated microvascular complications, but it was discontinued as it was found to be toxic at high concentrations (>10 mmol/L). The current article aims at glycation inhibition by conjugating gold nanoparticles (Gnp) with less concentration of AG (0.5-1.0 mmol/L). The HPLC results showed that AG-Gnp fairly hampers the formation of glycation adducts. Moreover, the studies revealed AG-Gnp mediated inhibition in the production of total-AGEs and - -(carboxymethyl)lysine (CML) in the diabetic rat model. This inhibition was found to be directly correlated with the antioxidant parameters, blood glucose, insulin, and glycosylated hemoglobin levels. Furthermore, the histopathology of AG-Gnp-treated rats showed good recovery in the damaged pancreatic tissue as compared to diabetic rats. We propose that this approach might increase the efficacy of AG at relatively low concentrations to avoid toxicity and might facilitate to overcome the hazardous actions of antiglycating drugs.

摘要

蛋白质发生糖基化,导致晚期糖基化终产物(AGEs)的产生,这些产物在糖尿病相关的继发性并发症的发生和发展中起着核心作用。氨基胍(AG)通过抑制活性羰基物质(RCS)如甲基乙二醛(MGO)的生成来充当抗糖基化剂。先前关于 AG 的抗糖基化行为的研究在治疗糖尿病相关的微血管并发症方面取得了有希望的结果,但由于在高浓度(>10mmol/L)下发现它具有毒性而被停止使用。本文旨在通过将金纳米粒子(Gnp)与浓度较低的 AG(0.5-1.0mmol/L)结合来抑制糖基化。HPLC 结果表明,AG-Gnp 相当程度地阻止了糖基化加合物的形成。此外,研究表明,AG-Gnp 介导抑制了糖尿病大鼠模型中总 AGEs 和 - -(羧甲基)赖氨酸(CML)的产生。这种抑制与抗氧化参数、血糖、胰岛素和糖化血红蛋白水平直接相关。此外,AG-Gnp 处理的大鼠的组织病理学显示,与糖尿病大鼠相比,受损的胰腺组织有了较好的恢复。我们提出,这种方法可以在相对较低的浓度下提高 AG 的疗效,以避免毒性,并可能有助于克服抗糖基化药物的危险作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b41/8137289/53e8e2bef213/BMRI2021-5591851.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b41/8137289/578b7bec89e8/BMRI2021-5591851.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b41/8137289/6b4b62c1d7d7/BMRI2021-5591851.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b41/8137289/53e8e2bef213/BMRI2021-5591851.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b41/8137289/578b7bec89e8/BMRI2021-5591851.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b41/8137289/6b4b62c1d7d7/BMRI2021-5591851.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b41/8137289/53e8e2bef213/BMRI2021-5591851.003.jpg

相似文献

1
Gold Nanoparticle-Bioconjugated Aminoguanidine Inhibits Glycation Reaction: An Study in a Diabetic Animal Model.金纳米粒子-生物缀合氨基胍抑制糖基化反应:糖尿病动物模型研究。
Biomed Res Int. 2021 May 12;2021:5591851. doi: 10.1155/2021/5591851. eCollection 2021.
2
Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats.氨基胍可抑制糖尿病大鼠的蛋白尿,但不能抑制其皮肤胶原蛋白中晚期糖基化终产物的形成。
Diabetes Res Clin Pract. 1999 Feb;43(2):81-9. doi: 10.1016/s0168-8227(98)00121-1.
3
Bioconjugation of gold nanoparticles with aminoguanidine as a potential inhibitor of non-enzymatic glycation reaction.金纳米粒子与氨基胍的生物缀合作为非酶糖基化反应的潜在抑制剂。
J Biomol Struct Dyn. 2021 Apr;39(6):2014-2020. doi: 10.1080/07391102.2020.1749131. Epub 2020 Apr 9.
4
Effect of age receptor blocker and/or anti-inflammatory coadministration in relation to glycation, oxidative stress and cytokine production in stz diabetic rats.年龄受体阻滞剂和/或抗炎药联合给药对链脲佐菌素诱导的糖尿病大鼠糖基化、氧化应激和细胞因子产生的影响。
Pharmacol Res. 2002 May;45(5):391-8. doi: 10.1006/phrs.2002.0979.
5
Inhibition of Advanced Glycation End Products Formation Attenuates Cardiac Electrical and Mechanical Remodeling and Vulnerability to Tachyarrhythmias in Diabetic Rats.抑制晚期糖基化终产物形成可减轻糖尿病大鼠心脏电机械重构和易发性室性心律失常。
J Pharmacol Exp Ther. 2019 Jan;368(1):66-78. doi: 10.1124/jpet.118.252080. Epub 2018 Oct 31.
6
Role of maltol in advanced glycation end products and free radicals: in-vitro and in-vivo studies.麦芽酚在晚期糖基化终产物和自由基中的作用:体外和体内研究
J Pharm Pharmacol. 2008 Apr;60(4):445-52. doi: 10.1211/jpp.60.4.0006.
7
Ellagic acid, a new antiglycating agent: its inhibition of Nϵ-(carboxymethyl)lysine.鞣花酸,一种新型糖化抑制剂:对 Nϵ-(羧甲基)赖氨酸的抑制作用。
Biochem J. 2012 Feb 15;442(1):221-30. doi: 10.1042/BJ20110846.
8
Curcumin, Alone or in Combination with Aminoguanidine, Increases Antioxidant Defenses and Glycation Product Detoxification in Streptozotocin-Diabetic Rats: A Therapeutic Strategy to Mitigate Glycoxidative Stress.姜黄素,单独或与氨基胍联合使用,可增加链脲佐菌素诱导的糖尿病大鼠的抗氧化防御和糖基化终产物解毒:减轻糖基化应激的治疗策略。
Oxid Med Cell Longev. 2020 May 20;2020:1036360. doi: 10.1155/2020/1036360. eCollection 2020.
9
Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications.氨基胍抑制氨基脲敏感胺氧化酶活性:对晚期糖基化及糖尿病并发症的影响。
Diabetologia. 1997 Nov;40(11):1243-50. doi: 10.1007/s001250050816.
10
Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-beta: implications for diabetic atherosclerosis.甲基乙二醛诱导晚期糖基化终末产物(AGEs)的形成及血小板衍生生长因子受体-β功能障碍:对糖尿病性动脉粥样硬化的影响
FASEB J. 2007 Oct;21(12):3096-106. doi: 10.1096/fj.06-7536com. Epub 2007 May 15.

引用本文的文献

1
Advanced Glycation End Products in Disease Development and Potential Interventions.疾病发展中的晚期糖基化终末产物及潜在干预措施。
Antioxidants (Basel). 2025 Apr 18;14(4):492. doi: 10.3390/antiox14040492.
2
In vivo glycation-interplay between oxidant and carbonyl stress in bone.骨中氧化剂与羰基应激之间的体内糖基化相互作用。
JBMR Plus. 2024 Aug 8;8(11):ziae110. doi: 10.1093/jbmrpl/ziae110. eCollection 2024 Nov.
3
Could nanotechnology improve exercise performance? Evidence from animal studies.纳米技术能提高运动表现吗?来自动物研究的证据。

本文引用的文献

1
Role of gold nanoparticles in advanced biomedical applications.金纳米颗粒在先进生物医学应用中的作用。
Nanoscale Adv. 2020 Jul 16;2(9):3764-3787. doi: 10.1039/d0na00472c. eCollection 2020 Sep 16.
2
Impact of Reactive Dicarbonyls on Biological Macromolecules- Role in Metabolic Disorders.活性二羰基化合物对生物大分子的影响——在代谢紊乱中的作用
Curr Protein Pept Sci. 2020;21(9):844-845. doi: 10.2174/138920372109201105114029.
3
An approach to unveil the structural alterations in d-ribose induced glycated fibrinogen.揭示 d-核糖诱导糖化纤维蛋白原结构变化的方法。
Braz J Med Biol Res. 2024 Apr 19;57:e13360. doi: 10.1590/1414-431X2024e13360. eCollection 2024.
4
SGLT2i relieve proteinuria in diabetic nephropathy patients potentially by inhibiting renal oxidative stress rather than through AGEs pathway.钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)可能通过抑制肾脏氧化应激而非晚期糖基化终末产物(AGEs)途径来减轻糖尿病肾病患者的蛋白尿。
Diabetol Metab Syndr. 2024 Feb 16;16(1):46. doi: 10.1186/s13098-024-01280-5.
5
Research Advances on the Damage Mechanism of Skin Glycation and Related Inhibitors.皮肤糖基化损伤机制及相关抑制剂的研究进展。
Nutrients. 2022 Nov 1;14(21):4588. doi: 10.3390/nu14214588.
6
Antiglycation and Antioxidant Effect of Nitroxyl towards Hemoglobin.硝酰基对血红蛋白的抗糖化和抗氧化作用
Antioxidants (Basel). 2022 Oct 11;11(10):2007. doi: 10.3390/antiox11102007.
J Biomol Struct Dyn. 2021 Sep;39(14):5209-5223. doi: 10.1080/07391102.2020.1802339. Epub 2020 Aug 8.
4
Bioconjugation of gold nanoparticles with aminoguanidine as a potential inhibitor of non-enzymatic glycation reaction.金纳米粒子与氨基胍的生物缀合作为非酶糖基化反应的潜在抑制剂。
J Biomol Struct Dyn. 2021 Apr;39(6):2014-2020. doi: 10.1080/07391102.2020.1749131. Epub 2020 Apr 9.
5
Glycation and Antioxidants: Hand in the Glove of Antiglycation and Natural Antioxidants.糖基化与抗氧化剂:抗糖基化与天然抗氧化剂的协同作用
Curr Protein Pept Sci. 2020;21(9):899-915. doi: 10.2174/1389203721666200210103304.
6
Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives.用纳米治疗和纳米诊断靶向癌细胞:现状和未来展望。
Semin Cancer Biol. 2021 Feb;69:52-68. doi: 10.1016/j.semcancer.2020.01.011. Epub 2020 Jan 31.
7
Physico-chemical Changes Induced in the Serum Proteins Immunoglobulin G and Fibrinogen Mediated by Methylglyoxal.由甲基乙二醛介导的血清蛋白免疫球蛋白G和纤维蛋白原中的物理化学变化
Curr Protein Pept Sci. 2020;21(9):916-923. doi: 10.2174/1389203720666190618095719.
8
Multiple Glycation Sites in Blood Plasma Proteins as an Integrated Biomarker of Type 2 Diabetes Mellitus.血浆蛋白质中的多个糖基化位点作为 2 型糖尿病的综合生物标志物。
Int J Mol Sci. 2019 May 10;20(9):2329. doi: 10.3390/ijms20092329.
9
Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: A review.治疗糖尿病患者晚期糖基化终产物的选择:综述。
Diabetes Res Clin Pract. 2019 Feb;148:54-63. doi: 10.1016/j.diabres.2018.11.016. Epub 2018 Nov 27.
10
Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging.糖基化损伤:主要病理生理紊乱和衰老的可能核心
Aging Dis. 2018 Oct 1;9(5):880-900. doi: 10.14336/AD.2017.1121. eCollection 2018 Oct.